Jacobs Solutions (NYSE:J) Azioni

JACOBS SOLUTIONS INC

Jacobs Solutions

Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.

Jacobs Engineering Group

Jacobs Solutions Inc

Janus Henderson AAA CLO ETF

JAC JAPAN CO LTD ORD by Jac Japan Co., Ltd.

JAC Recruitment Co Ltd

Jack In The Box Inc

JACO ELECTRONICS INC by JACO Electronics, Inc.

Jaco Electronics Inc

Jackson Acquisition Company II Class A Ordinary Shares

Jackson Acquisition Co II

Jackson Acquisition Company II Units, each consisting of one Class A ordinary share and one right to acquire one-tenth (1/10) of one Class A ordinary share

JACCS CO by Jaccs Co.

Jackson Acquisition Company II Rights, each right to acquire one-tenth (1/10) of one Class A ordinary share

JADE ART GROUP INC by Jade Art Group, Inc.

Jade Art Group Inc

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active Developing Markets Equity ETF

Jaguar Mining Inc

JAAG ENTERPRISES LTD. by JAAG Enterprises Ltd.

JAAG Enterprises Ltd

GREEN STREET CAPITAL CORP by Green Street Capital Corp

Green Street Capital Corp

Jaguar Health Inc

JUSTIN ALLEN HLDGS LTD by JUSTIN ALLEN HLDGS LTD.

JAPAN AIRPORT TERMINAL by Japan Airport Terminal

Japan Airport Terminal Co Ltd

JAJ DISTRIBUTION SA by JAJ DISTRIBUTION SA

Innovator Equity Defined Protection ETF - 6 Mo Jan/Jul

Jakks Pacific Inc

JAKKS PACIFIC 6% PFD A by JAKKS Pacific, Inc.

ADAMS (JOHN) LIFE CORP by Adams (JOHN) Life Corp.

John Adams Life Corp

Jamf Holding Corp

Tuktu Resources Ltd

Jammin Java Corp

Innovator ETFs Trust Premium Income 10 Barrier ETF January

Innovator ETFs Trust Innovator Premium Income 20 Barrier ETF - January

Innovator ETFs Trust Innovator Premium Income 30 Barrier ETF - January

Janel Corp

First Trust Exchange-Traded Fund VIII FT Vest U.S. Equity Max Buffer ETF - January

PGIM S&P 500 Buffer 12 ETF - January

Innovator ETFs Trust US Equity Prem Income 40 Barrier ETF - January

AllianzIM U.S. Large Cap Buffer10 Jan ETF

AIM ETF Products Trust AllianzIM U.S. Equity Buffer15 Uncapped Jan ETF

AllianzIM U.S. Large Cap Buffer20 Jan ETF

Janux Therapeutics Inc

TrueShares Structured Outcome (January) ETF

Japan Tobacco Inc

JAPAN SYS TECHNIQUES CO by Japan Systems Techniques Co. Ltd.

Japan System Techniques Co Ltd

JAPAN AIRLINES UNSP/ADR by Japan Airlines Ltd

Japan Airlines Co Ltd

Jupiter Acquisition Corp

Jupiter Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Jupiter Acquisition Corp Warrants (04/09/2025)

JARDINE MATHESON HLDG ORD by Jardine Matheson Holdings Ltd.

Jardine Matheson Holdings Ltd

JasmyCoin - United States Dollar

JASTEC Co Ltd

JASMINE INTL PLC NVDR by Jasmine International Public Co., Ltd.

Jasmine International PCL

JAPAN TRANSCITY CORP ORD by Japan Transcity Corp.

Japan Transcity Corp

JPMorgan Active Value ETF

Vinyl Group Ltd

PT JAYA KONSTRUKSI NEW by PT Jaya Konstruksi Manggala Pratama TBK

PT Jaya Konstruksi Manggala Pratama Tbk

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

JULIUS BAER GRUPPE NAMEN by Julius Baer Group Ltd.

Julius Baer Gruppe AG

JULIUS BAER GRP UNSP/ADR by Julius Baer Group Ltd.

Janus Detroit Street Trust Janus Henderson B-BBB CLO ETF

JBDI Holdings Ltd

JOLLIBEE FOODS CORP by Jollibee Foods Corp.

Jollibee Foods Corp

JOLLIBEE FOODS UNSP/ADR by Jollibee Foods Corp.

JBG SMITH Properties

JB HI-FI LTD UNSP/ADR by JB Hi-Fi Limited

JB Hi Fi Ltd

J.B. Hunt Transport Services, Inc. - Common Stock

JB Hunt Transport Services Inc

Janus International Group, Inc. Common Stock

Janus International Group Inc

JUMBO INTERACTIVE LTD by JUMBO INTERACTIVE LTD.

Jumbo Interactive Ltd

Jade Biosciences Inc

Lehman ABS 3.50 3.50% Adjustable Corp Backed Tr Certs GS Cap I

Jabil Inc

JetBlue Airways Corporation - Common Stock

JetBlue Airways Corp

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active Bond ETF

SWISSCANTO ETF PREC METLS by Julius Baer Precious Metals

JACOBIO PHARMACEUTICALS by Jacobio Pharmaceuticals Group Co Ltd.

Jacobio Pharmaceuticals Group Co Ltd

JBS SA

John B. Sanfilippo & Son, Inc. - Common Stock

John B Sanfilippo & Son Inc

Jbt Bancorp Inc

JBT Marel Corp

JAMES BAY MINERALS LTD by JAMES BAY MINERALS LTD

JB&ZJMY HOLDING CO by JB&ZJMY Holding Company, Inc.

JB&ZJMY Holding Co Inc

JCDecaux SE

Nuveen Core Equity Alpha Fund Common Shares of Beneficial Interest

Nuveen Core Equity Alpha Fund

JPMORGAN CHINESE INV TR by JPMorgan Chinese Investment Trust PLC

J.P. Morgan Exchange-Traded Fund Trust JPMorgan Active China ETF

Johnson Controls International plc Ordinary Share

Johnson Controls International PLC

JPMorgan Core Plus Bond ETF

J P MORGAN EXCHANGE-TRADED FD TR JPMorgan Inflation Managed Bond ETF

JCR PHARMACEUTICALS CO by JCR PHARMACEUTICALS CO LTD.

JCR Pharmaceuticals Co Ltd

JE Cleantech Holdings Limited - Ordinary Shares

JE Cleantech Holdings Ltd

Jewett-Cameron Trading Company - Common Shares

Jewett-Cameron Trading Co Ltd

JPMorgan Carbon Transition U.S. Equity ETF

JARDINE CYCLE&CARRAGE LTD by Jardine Cycle & Carriage Limited

Jardine Cycle & Carriage Ltd

JARDINE CYCL&CARRGE U/ADR by Jardine Cycle & Carriage Limited

JD.com, Inc. - American Depositary Shares

JD.com Inc

JUDO CAP HLDGS LTD by JUDO CAP HLDGS LTD.

Judo Capital Holdings Ltd

JD SPORTS FASHION PLC NEW by JD Sports Fashion PLC

JD Sports Fashion PLC

JDE Peets NV

DA Davidson analyst Michael Shlisky maintains Timken (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>) with a Neutral and raises the price target from $66 to $71.

News

Price Target

Analyst Ratings

DA Davidson Maintains Neutral on Timken, Raises Price Target to $71

RBC Capital analyst Elvira Scotto maintains Venture Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Outperform and lowers the price target from $15 to $14.

RBC Capital Maintains Outperform on Venture Global, Lowers Price Target to $14

Macro Economic Events

Global

Economics

Citigroup CEO Jane Fraser, Speaking At Milken Institute Global Conference Says Certainly Been A Fluid Few Weeks; Most Companies Are A Bit In Limbo Land, There's A Wait And See Going On; Most Of Clients Can Absorb 10% Tariffs

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) has outperformed the market over the past 5 years by 7.05% on an annualized basis producing an average annual return of 21.12%. Currently, Uber Technologies has a market capitalization of $178.71 billion. 
Buying $1000 In UBER: If an investor had bought $1000 of UBER stock 5 years ago, it would be worth $2,762.85 today based on a price of $85.45 for UBER at the time of writing.
<h3>Uber Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746459918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

UBER

$1000 Invested In Uber Technologies 5 Years Ago Would Be Worth This Much Today

DA Davidson analyst Gil Luria maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and raises the price target from $115 to $125.

DDOG

DA Davidson Maintains Buy on Datadog, Raises Price Target to $125

RBC Capital analyst Arun Viswanathan maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Sector Perform and lowers the price target from $28 to $25.

RBC Capital Maintains Sector Perform on Olin, Lowers Price Target to $25

Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) stock was trading lower on Monday after the company announced that Warren Buffett, 94, will <a target="_blank" href="https://www.benzinga.com/25/05/45187070/warren-buffett-retires-after-decades-of-dominancefrom-tim-cook-to-mark-cuban-worlds-top-business-leaders-react-to-the-investment-icons-exit" rel="noreferrer noopener">step down as</a> CEO.
On May 4, Berkshire&#8217;s board voted to appoint Greg Abel as CEO, effective January 1, 2026, during its <a target="_blank" href="https://www.benzinga.com/news/management/25/05/45188605/youve-got-to-check-emotions-at-the-door-warren-buffett-offers-timeless-investing-wisdom-amid-market-turmoil" rel="noreferrer noopener">60th annual shareholders </a>meeting. Buffett will remain Chairman of the Board.
Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) CEO&nbsp;Tim Cook, CNBC&#8217;s&nbsp;Jim Cramer, and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) co-founder&nbsp;Bill Gates expressed their admiration for Buffett.
Also Read: <a target="_blank" href="https://www.benzinga.com/personal-finance/25/02/43496879/elon-musk-said-warren-buffett-managed-to-create-a-great-image-as-a-kindly-grandfather-but-thinks-thats-maybe-overstating-the-case" rel="noreferrer noopener">Elon Musk Said Warren Buffett &#8216;Managed To Create A Great Image As A Kindly Grandfather&#8217; – But Thinks That&#8217;s &#8216;Maybe Overstating The Case&#8217;</a>
Despite accumulating a <a target="_blank" href="https://www.benzinga.com/markets/25/05/45190271/warren-buffett-and-charlie-mungers-timeless-wisdom-draws-bill-ackmans-praise-this-is-a-great-book-key-les" rel="noreferrer noopener">record $348 billion</a> cash reserve, Buffett said he is ready to deploy $20 billion or even $100 billion&nbsp;given the right opportunity.
This cash position follows Berkshire&#8217;s sale of two-thirds of its Apple position last year. Buffett has also signaled conviction in&nbsp;Berkshire&#8217;s $20 billion Japanese trading companies.
In the <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45183890/berkshire-hathaways-q1-2025-earnings-plunge-amid-tariff-concerns-operating-profit-fell-14-cash-hit-a-record" rel="noreferrer noopener">first quarter of&nbsp;2025</a>,&nbsp;Berkshire Hathaway&#8217;s operating earnings fell 14% to $9.64&nbsp;billion. The result was driven by a 48.6% plunge&nbsp;in insurance-underwriting profit, which&nbsp;came in at $1.34 billion&nbsp;for the first quarter, down&nbsp;from $2.60 billion a year&nbsp;prior. Berkshire attributed this to the Southern California wildfires, which&nbsp;led to a $1.1 billion&nbsp;loss in the first quarter. The company also&nbsp;suffered a ~$713 million&nbsp;loss related to foreign exchange due to&nbsp;the dollar losing value.
Price Action: BRK/A stock was down 4.37% at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45155666/robinhood-stock-falls-after-analysts-cite-weak-crypto-volumes-and-market-headwinds-in-q2-outlook" target="_blank" rel="noreferrer noopener">Robinhood Stock Falls After Analysts Cite Weak Crypto Volumes And Market Headwinds In Q2 Outlook</a></li>
</ul>
Photo courtesy: mark reinstein via Shutterstock

Management

Movers

AAPL

MSFT

Berkshire Hathaway Stock Falls Following Buffett's Retirement As CEO

<a href="https://www.youtube.com/live/qhAQ_sImdOM" title="https://www.youtube.com/live/qhAQ_sImdOM">https://www.youtube.com/live/qhAQ_sImdOM</a>

Politics

General

U.S. Treasury's Bessent Says If We Can Take Away The Credit Risk Of The U.S. Government, Interest Rates Will Come Down; We Want To Bring Down Federal Deficit By Maybe 1% Per Year

Compass Point analyst Casey Alexander downgrades Acushnet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLF#NYSE">GOLF</a>) from Buy to Neutral and lowers the price target from $80 to $71.

Downgrades

GOLF

Compass Point Downgrades Acushnet Holdings to Neutral, Lowers Price Target to $71

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Alvotech&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
As of April 30, 2025, Selarsdi is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn&#8217;s disease, and ulcerative colitis.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43910567/sanofi-teva-unveil-new-detailed-data-for-duvakitug-study-supporting-overall-efficacy-for-common-inflammatory-bowel-disease" rel="noreferrer noopener">Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease</a>
&#8220;Teva&#8217;s recent launch of two biosimilars – SELARSDI and EPYSQLI – coupled with a rich pipeline of assets expected to launch over the next few years, position Teva to establish a strong leadership position in the growing landscape of biosimilars and to drive growth for the company as it embarks on the next phase of its strategy,&#8221; said Thomas Rainey, senior vice president, U.S. Biosimilars at Teva.
Approved <a target="_blank" href="https://www.globenewswire.com/news-release/2025/05/05/3073922/0/en/Teva-and-Alvotech-Announce-FDA-Approval-of-Interchangeability-for-SELARSDI-ustekinumab-aekn-with-Stelara-ustekinumab.html" rel="noreferrer noopener">presentations</a> of Selarsdi are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection, 45 mg/0.5 mL in a single-dose vial for subcutaneous injection and 130 mg/26 mL in a single-dose vial for intravenous infusion.
Alvotech developed and produces Selarsdi using Sp2/0 cells and a continuous perfusion process, which are the same type of host cell line and process used in the production of Stelara.
In August 2020, Teva and Alvotech entered into a strategic partnership to exclusively commercialize five Alvotech biosimilar product candidates. In July 2023, the partnership was extended to include two additional biosimilars and new presentations of two previously partnered products.
<ul>
<li>Alvotech manages development and manufacturing, while Teva is responsible for exclusive commercialization in the U.S., leveraging its experience and extensive sales and marketing infrastructure.</li>
<li>Two biosimilars developed under the Teva &#8211; Alvotech partnership have been granted FDA approval with interchangeability, including Selarsdi. In February 2024, the FDA approved Simlandi (adalimumab-ryvk), the first high-concentration, a citrate-free interchangeable biosimilar to AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Humira&nbsp;(adaliumumab), which was launched in the U.S. in May 2024.</li>
</ul>
Biologics License Applications (BLAs) for three additional biosimilar candidates developed by Alvotech in partnership with Teva have been accepted for review by the FDA:
<ul>
<li>AVT05, a proposed biosimilar for Johnson &amp; Johnson&#8217;s Simponi (golimumab) and Simponi Aria (golimumab).</li>
<li>AVT06, a proposed biosimilar for Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Eylea (aflibercept).</li>
<li>Biosimilar User Fee Act (BsUFA) goal dates for approval for these BLAs are in Q4 2025.</li>
</ul>
Price Action: TEVA stock is up 2.10% at $16.53 and ALVO stock is up 0.67% at $8.22 at the last on check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45179379/motorolas-resilient-orders-solid-margins-drive-analyst-confidence-despite-tariff-risks" target="_blank" rel="noreferrer noopener">Motorola&#8217;s Resilient Orders, Solid Margins Drive Analyst Confidence Despite Tariff Risks</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

ABBV

ALVO

REGN

TEVA

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?

Editor&rsquo;s note: This article was originally published in July 2024. It was updated in May 2025 to reflect the continued growth of Educannabis.
&quot;I&#39;ve spent my life with the romantic dream of saving the world,&quot; declares the Mexican entrepreneur Luis Fernando Campos Aguirre, setting the tone for a conversation that transcends the ordinary bounds of cannabis advocacy. A biotechnologist with a keen focus on environmental and social causes, Luis Fernando&mdash;better known as Luis Fer&mdash;has channeled his lifelong passion into Educannabis, a project conceived to help demystify cannabis and empower its consumers through education.
Founded in 2021 alongside friends Yowua Cobos and Jos&eacute; Garc&iacute;a Varela, Educannabis was born from a simple yet profound mission: to provide clear, accurate and stigma-free information about the plant. The platform quickly gained traction, amassing more than 1.2 million followers on TikTok and becoming the largest cannabis education platform on social media in the Spanish-speaking world. Luis Fer&rsquo;s vision, driven by his lifelong passion for making a positive impact, began to take shape as he and his team tackled the misinformation surrounding cannabis.
Also read:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/06/39114436/how-3-chilean-brothers-built-a-global-cannabis-platform-embraced-by-big-sponsors-like-adidas-and">How 3 Chilean Brothers Built A Global Cannabis Platform Embraced By Big Sponsors Like Adidas And Crocs</a>
&quot;We want to help everyone who was too embarrassed to raise their hand for help,&quot; says Luis Fer. This ethos drives Educannabis&#39; content, which ranges from scientific explanations of cannabis to practical advice for safe consumption&mdash;mostly in very short-form videos.
<script async src="https://www.tiktok.com/embed.js"></script><h3>&lsquo;So Far From God, So Close To The U.S.&rsquo;</h3>
In Mexico, where cannabis legislation is in flux, Educannabis stands as a trusted source of reliable information. The country&rsquo;s Supreme Court declared cannabis prohibition unconstitutional in 2018, yet the legislative framework remains incomplete, leaving consumers in a legal gray area. However, some licenses for hemp cultivation have been granted, as first reported by Latin American media outlet <a href="https://elplanteo.com/mexico-cofepris-autoriza-cultivo-de-canamo/" rel="nofollow noopener noreferrer" target="_blank">El Planteo</a>. Luis Fer is candid about the challenges: &quot;The legislation is not up to the industry or its citizens,&quot; he laments. Despite the bureaucratic hurdles, he encourages individuals to pursue legal avenues for personal cultivation and consumption, emphasizing the importance of doing so for their safety and peace of mind.
The influence of the United States, both culturally and geographically close to Mexico, plays a significant role in shaping the cannabis landscape. &quot;The trends of the largest market in the world (the U.S.) have always directly affected Mexico, and I&rsquo;m sure the cannabis industry is no exception,&quot; says Luis Fer.&nbsp;
There&rsquo;s a well-known Mexican saying&mdash;often attributed to former leader Porfirio D&iacute;az&mdash;that reflects the country&rsquo;s complex relationship with its northern neighbor: &quot;Poor Mexico, so far from God, so close to the United States.&quot; Luis Fer believes that the anticipated federal regulation of cannabis in the U.S. will spur Mexican legislators to finally establish a comprehensive legal framework. &quot;The current [Mexican] government is in favor of legalization, and I&rsquo;m convinced that this will be the term where we see the harvest of the efforts that so many activists have planted,&quot; he asserts.
<h3>The &lsquo;Broccoli&rsquo; Approach</h3>
Navigating the tricky waters of social media has not been easy for the Educannabis team, especially given the platforms&#39; stringent content guidelines around cannabis. Nonetheless, it has managed to skirt these bans by focusing on education rather than promotion. &quot;Our aim is to empower people with knowledge, enabling them to make informed decisions about their cannabis use,&quot; Luis Fer states. This commitment to education is reflected in the platform&rsquo;s content, which includes tips on everything from passing drug tests to talking with skeptical family members about cannabis consumption.
&quot;From the beginning of the project on YouTube, we knew we had to make efforts across different social networks. The challenge of talking about cannabis on platforms that censor our content makes everything much more fun. This desire to create content to help others has allowed us to grow as a team and understand the algorithm a little more in a game where we will never be experts because it changes every day,&quot; says Luis Fer. This meticulous attention to detail, from the content itself to its presentation, has been key to its growth.
The team&rsquo;s creative approach has enabled it to navigate censorship effectively. By using code phrases like &quot;magic broccoli&quot; to refer to cannabis, the team has managed to discuss the topic without violating platform guidelines. &quot;It started as a local joke, a term to talk about cannabis in public that only people in the conversation would understand,&quot; Luis Fer explains. Today, &quot;broccoli&quot; is widely recognized and used within the cannabis community&mdash;even becoming the center of a <a href="https://boardroom.tv/weedmaps-cannabis-censorship-brock-ollie/" rel="nofollow noopener noreferrer" target="_blank">well-known advertising campaign</a> in the U.S. in 2022.
<h3>The Expanding Horizon Of Educannabis And Latin American Cannabis Markets</h3>
As Educannabis evolves, the size and potential of the cannabis market in Latin America become increasingly significant. Prohibition Partners analysts estimate that the Latin American cannabis market could skyrocket to billions in sales in a few years, with both medical and recreational use gaining legal status in countries like Uruguay, Colombia, Argentina and Mexico. The market value is expected to surge from $168 million in 2020 to an estimated $824 million by the end of 2024, according to <a href="https://prohibitionpartners.com/reports/the-latin-america-and-caribbean-cannabis-report-second-edition/" rel="nofollow noopener noreferrer" target="_blank">Prohibition Partners</a>. This trend is fostered by favorable legislation, a strategic location and economic benefits, such as production costs up to 80% lower than in North America.
In Mexico specifically, the medical cannabis market was valued at $7.8 million in 2023 and is projected to grow significantly, potentially reaching $117.7 million by 2030, as reported by <a href="https://www.grandviewresearch.com/industry-analysis/mexico-medical-cannabis-market" rel="nofollow noopener noreferrer" target="_blank">Grand View Research</a>. This rapid growth is driven by the impending legalization of recreational cannabis, which is expected to end criminal drug trafficking and shift the business to legal cannabis entrepreneurs. Comparatively, the U.S. cannabis market is already substantial, with projections estimating it to reach $53.5 billion by 2027, according to <a href="https://mjbizdaily.com/us-cannabis-sales-estimates/" rel="nofollow noopener noreferrer" target="_blank">MJBizDaily</a>.
<h3>Combatting Censorship With &lsquo;Censura&rsquo;</h3>
Educannabis&#39; journey has been marked by innovation and adaptability, traits that have enabled it to thrive despite significant challenges. One of the most pressing issues faced by cannabis consumers in Mexico is the pervasive stigma and misinformation surrounding the plant. &quot;Security and disinformation go hand in hand and are consequences of illegality and social prejudices,&quot; says Luis Fer. This stigmatization often forces individuals to hide their consumption, putting them at risk.
<script async src="https://www.tiktok.com/embed.js"></script>Educannabis addresses these challenges head-on by providing a wealth of information that transforms into knowledge. &quot;We explain the risks of exposing oneself to obtain cannabis, the advantage of investing in quality products with certifications or chromatographic tests, and give consumers virtual hugs, reminding them that they are not bad people for consuming cannabis,&quot; Luis Fer voices. This supportive approach helps reduce stigma and promotes a culture of responsible consumption.
The team is also dedicated to evolving with the ever-changing landscape of social media. It created &quot;Censura&quot; (&ldquo;censorship&rdquo; in Spanish), a marketing agency designed to help nascent industries navigate restrictions without violating platform rules. &quot;Knowing the terms and conditions of the networks where we exist is just the first step; they are constantly changing and we constantly have to change with them,&quot; says Luis Fer.
For now, Educannabis remains focused on its core mission: to educate and empower cannabis consumers. Its efforts to demystify cannabis and promote responsible consumption have resonated with a broad audience, from seasoned users to curious newcomers. By providing reliable information and fostering a supportive community, Educannabis is helping to shape a more informed and accepting society.
Its journey is far from over. With a solid foundation and a clear vision, Luis Fer and his team are poised to continue making a significant impact in the world of cannabis education.
Follow me on <a href="https://www.twitter.com/javierhasse" rel="nofollow noopener noreferrer" target="_blank">Twitter</a> or <a href="https://www.linkedin.com/in/javierhasse/" rel="nofollow noopener noreferrer" target="_blank">LinkedIn</a>. Check out my <a href="https://elplanteo.com/" rel="nofollow noopener noreferrer" target="_blank">website</a> or some of my other work <a href="https://benzinga.com/cannabis" rel="nofollow noopener noreferrer" target="_blank">here</a>.
This article was originally published on <a href="https://www.forbes.com/sites/javierhasse/2024/07/09/saving-the-world-with-broccoli-how-one-mexican-cannabis-platform-got-11m-tiktok-followers-through-educational-content/" rel="nofollow noopener noreferrer" target="_blank">Forbes</a> and appears here with permission. The article is from an external source. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.
Photo courtesy of Educannabis.

Cannabis

Entertainment

Education

Markets

The Broccoli Hack: How Mexican Creators Bypassed TikTok's Rules To Teach Millions About Cannabis

RBC Capital analyst Mike Dahl maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Sector Perform and lowers the price target from $130 to $119.

RBC Capital Maintains Sector Perform on Mohawk Industries, Lowers Price Target to $119

RBC Capital analyst Kenneth Lee maintains MSC Income Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSIF#NYSE">MSIF</a>) with a Outperform and lowers the price target from $19 to $18.

MSIF

RBC Capital Maintains Outperform on MSC Income Fund, Lowers Price Target to $18

CIBC analyst Mark Jarvi maintains Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>) with a Outperformer and lowers the price target from $31 to $30.

CIBC Maintains Outperformer on Brookfield Renewable, Lowers Price Target to $30

RBC Capital analyst Kenneth Lee maintains Kayne Anderson BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBDC#NYSE">KBDC</a>) with a Outperform and lowers the price target from $18 to $17.

KBDC

RBC Capital Maintains Outperform on Kayne Anderson BDC, Lowers Price Target to $17

CIBC analyst Krista Friesen maintains Magna International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) with a Neutral and raises the price target from $33 to $38.

CIBC Maintains Neutral on Magna International, Raises Price Target to $38

WIIM

PAAS

RGLD

SBSW

Shares of precious metals stocks are trading higher amid a rise in the price of gold and silver.

CIBC analyst Hamir Patel maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Outperformer and lowers the price target from $47 to $44.

Comments

Jacobs Solutions

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO